Clinical Trial

Collection of Blood Samples for New Diagnostic Devices 2

Study acronym: NOVEL-2
Recruiting
View on ClinicalTrials.gov →
Summary
To research and develop new state of the art diagnostic biomarkers on the LumiraDx Platform that are comparable to the approved gold standard reference methods and will radically enhance clinicians and patients ability to monitor health conditions and improve outcomes by delivering the results near patient at the point of care.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-10-03; most recent amendment 2026-04-17.
Trial Details
NCT Number NCT05568966
Lead Sponsor LumiraDx UK Limited
Conditions Embolism and Thrombosis, Cardiovascular, Renal, Inflammation, Infections
Enrollment 20,000 participants
Start Date 2022-07-11
Primary Completion 2026-08-20 (estimated)
Study Completion 2026-08-20 (estimated)
Updated on ClinicalTrials.gov 2026-04-22